Article Highlight: In the first several years after new cholesterol-lowering drugs called PCSK9 inhibitors entered the market, their use was generally low, and they were predominantly prescribed by cardiologists for patients with cardiovascular disease. These findings were based on a review of records from nearly 4 million patients with high cholesterol or cardiovascular disease who were identified using electronic health record data from several PCORnet partner networks. The review demonstrated the power of PCORnet to efficiently deliver rapid and reliable responses to stakeholder-prioritized questions. The results were published in the Journal of the American Heart Association.
- Has Results